Real-world costs and outcomes in metastatic renal cell carcinoma patients treated by targeted therapies: a cohort study from the French health insurance database.

CONCLUSION: This descriptive study showed that the economic burden of mRCC is substantial with oral targeted therapies accounting for 53% of the PPPM. OS and PFS in real life are poorer than observed in clinical trials. PMID: 28748721 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research